Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity
Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I rate TEVA stock as a Strong Buy.
Why Teva Pharmaceutical Stock Is Sinking Today
Shares of Teva Pharmaceutical Industries ( TEVA -13.66%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.86%) and Nasdaq Composite ( ^IXIC -1.18%) lost 0.5% and 0.9%, respectively.
Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday?
We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands among Wednesday’s worst-performing stocks.
Teva Pharma CEO: Guidance based on the new Teva that grows every year
Richard Francis, Teva Pharmaceuticals CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, drug price negotiations, and much more.
Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript
Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call. My name is Alex, and I will be coordinating the call today. [Operator instructions] And I hand it over to your host,
Teva, despite delivering in 2024, startles investors with subdued 2025 guidance
Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year appears to have investors spooked. | Despite finishing strong in 2024, Teva’s cautious approach to the new year appears to have investors spooked.
Teva falls sharply on disappointing 2025 guidance
"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products and key innovative products," said Teva CEO.
Teva Pharmaceutical shares tumble as 2025 outlook disappoints
NEW YORK - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported fourth-quarter earnings that beat analyst estimates, but its shares fell sharply as the company's 2025 outlook came in below expectations.
Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Teva Pharm tops quarterly estimates but 2025 earnings outlook falls short
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit ...
Teva on track for worst intraday loss in years on guidance miss
Teva Pharmaceutical (TEVA) stock falls as the generic drugmaker with its Q4 2024 results set its 2025 earnings outlook below ...
Teva price target lowered to $27 at UBS, says pullback ‘somewhat unfair’
UBS lowered the firm’s price target on Teva (TEVA) to $27 from $30 and keeps a Buy rating on the shares. UBS says the pullback on the stock ...
Teva (yes, like the sandals) makes winter boots now. We tested them in a polar vortex.
Teva’s first pair of true winter boots deliver on their promises. They’re not meant for arctic adventures but are great at ...
Pike Road native, Buckeyes’ RB Quinshon Judkins enters NFL Draft
Quinshon Judkins is entering the 2025 NFL Draft. Quinshon’s mother Teva confirmed the news to WSFA 12 Sports Director Rosie Langello on Friday morning.
Teva price target lowered to $26 from $28 at Barclays
Barclays lowered the firm’s price target on Teva (TEVA) to $26 from $28 and keeps an Overweight rating on the shares. The post-earnings selloff ...
Hosted on MSN1d
Teva Stock Dives 14%. Why Its CEO Says It's A Victim.
Teva Pharmaceutical is a victim of its own success, Chief Executive Richard Francis said Wednesday as Teva stock plummeted on ...